Nord Anglia Education, Inc.

NORD

BEVERLY HILLS, California, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, today announced the formation of a new company, NoviThera Aps (“NoviThera”), with the objective to research and develop a novel and unique Monoclonal antibody (MaB) as a novel innovative therapy for the treatment of psoriasis. Psoriasis is an Immune-medicated inflammatory disease that causes keratinocyte hyperproliferation and inflammation.

BEVERLY HILLS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announces it has applied to uplist its common stock (the “Common Stock”) to the Nasdaq Capital Market (“Nasdaq”). The Common Stock will continue to trade on the OTCQB Market until the uplisting is approved.

Beverly Hills, California, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a business accelerator and holding company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, announced today that Henrik Keller resigned from the Board of Directors (the “Board”) of Nordicus to pursue other interests; that the Board has been increased from three to five members; and that Torben Jensen, Kim T. Mücke and Andrew J. Ritter have been appointed to fill the vacancies on the Board.

BEVERLY HILLS, California, April 03, 2025 (GLOBE NEWSWIRE) -- Bio-Convert A/S (“Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announces it has received positive and constructive feedback from the Danish Medicine Agency (“DKMA”) for its lead drug candidate, QR-02 for the treatment of oral leukoplakia.

BEVERLY HILLS, California, April 02, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, today announced positive efficacy results for its lead periodontitis candidate, QR-01, in a preclinical study involving dogs diagnosed with periodontitis.

BEVERLY HILLS, California, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announces a strategic partnership with Syngene International Limited (“Syngene”),

BEVERLY HILLS, California, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, has successively completed its first toxicity study for QR-01, a novel treatment for aggressive periodontitis.

BEVERLY HILLS, California, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bio-Convert ApS (“Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announces the groundbreaking development of QR-02, a unique and proprietary oral topical treatment designed to address oral leukoplakia with moderate to severe dysplasia, a potentially precancerous condition affecting millions worldwide.

BEVERLY HILLS, California, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S, a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, has developed a novel, proprietary dental gel that represents a significant breakthrough in the long-term treatment of periodontitis.

BEVERLY HILLS, California, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announced today that its subsidiary, Orocidin A/S, will initiate its toxicity program for Orocidin (QR-01) in January 2025. The program is expected to conclude by the third quarter of 2025, paving the way for Orocidin to launch its first pilot efficacy study in patients by the end of 2025.